LUNG CANCER

Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.

The phase 3 KEYNOTE-598 study of pembrolizumab plus ipilimumab in a population of patients with metastatic non–small cell lung cancer has been discontinued for futility.

Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.

As the field of lung cancers continues to lean further into the precision medicine era, KRAS G12C has become an emerging actionable target for which multiple therapies are under development, said Bob T. Li, MD.

Many challenges have arisen as a result of the coronavirus 2019 pandemic, which is still impacting nations across the world. In the United States, oncologists have initiated research to provide wider understanding of the virus and the threat it poses to patients with lung cancer.

Brett Simon, MD, PhD, discusses an ongoing program at his institution that aims to improve symptoms and outcomes for patients with lung cancer who have undergone surgery.

In an interview with Targeted Oncology, David M. Waterhouse, MD, MPH, discussed the evolving role of genomic testing and related challenges in the lung cancer treatment paradigm as immunotherapies and targeted therapies continue to expand the field.

In an interview with Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Tumor mutational burden has been correlated with response to immunotherapy use in patients treated with immune checkpoint blockade. However, use of this biomarker has been challenged along the way with various criticisms of validity and routine use.

Mark G. Kris, MD, discusses 1 of the major topics of discussion from the 15th Annual New York Lung Cancers Symposium, among other areas of focus at the meeting.

An important milestone in the treatment landscape of extensive-stage small cell lung cancer has been trials of first-line chemoimmunotherapy. However, a study that requires better understanding of the methods and can be used to determine patients who are likely to experience durable benefits to therapy is currently concentrated.

The use of chemoimmunotherapy as treatment of patients with treatment-naive stage IIIB or IV nonsquamous non–small cell lung cancer was the topic of a Targeted Oncology Case Based Peer Perspective discussion led by Charu Aggarwal, MD, MPH.

A selection of therapies exist for patients with oncogene-driven lung cancer. Ticiana Leal, MD, discussed these options with a group of peers during a Targeted Oncology Case Based Peer Perspectives event.

Benjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.

The FDA has accepted the supplemental Biologics License Application for cemiplimab-rwlc and granted it Priority Review for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer with ≥50% PD-L1 expression.

During a Targeted Oncology Case Based Peer Perspective event, Jarushka Naidoo, MBBCh, discussed a case of a 63-year-old patients with non–small cell lung cancer.

Afatinib, an FDA-approved frontline treatment for patients with metastatic non–small cell lung cancer, has now demonstrated efficacy and tolerable safety in the second-line setting of metastatic squamous cell carcinoma of the lung

Encouraging anti-tumor activity was observed with the combination of quavonlimab and pembrolizumab when given as frontline therapy to patients with advanced non–small cell lung cancer in a phase 1 study.

Four-year follow-up data from cohort G KEYNOTE-021 reinforced the use of the immune checkpoint inhibitor pembrolizumab in patients with advanced non–small cell lung cancer.

During a Medical Crossfire at the 21st Annual International Lung Cancer Congress, Paul A. Bunn, Jr, MD, debated with Karen L. Reckamp, MD, MS, about frontline single-agent immune checkpoint inhibitors versus combined chemotherapy and immunotherapy for the treatment of patients with advanced NSCLC.

During a Targeted Oncology Case Based Peer Perspectives event, Konstantinos Arnaoutakis, MD, discussed the case of a 63-year-old patient with non–small cell lung cancer.

Multiple agents are now challenging chemotherapy as the golden standard in the front-line setting of advanced non–small cell lung cancer.